RBC Europe’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

RBC Europe’s Portfolio SRRA Stock Details SRRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-24	Closed	-$526	–	1264
2021 Q3	$526	Hold	24	–	–	﹤0.01%	1196
2021 Q2	$467	Hold	24	–	–	﹤0.01%	1192
2021 Q1	$414	Hold	24	–	–	﹤0.01%	1147
2020 Q4	$385	Hold	24	–	–	﹤0.01%	1118
2020 Q3	$256	Hold	24	–	–	﹤0.01%	1070
2020 Q2	$290	Hold	24	–	–	﹤0.01%	1036
2020 Q1	$236	Hold	24	–	–	﹤0.01%	1010
2019 Q4	$334	Hold	24	–	–	﹤0.01%	1017
2019 Q3	$381	Hold	24	–	–	﹤0.01%	1015
2019 Q2	$546	Hold	24	–	–	﹤0.01%	1027
2019 Q1	$1.67K	Hold	24	–	–	﹤0.01%	1003
2018 Q4	$1.29K	Hold	24	–	–	﹤0.01%	1019
2018 Q3	$1.66K	Hold	24	–	–	﹤0.01%	1053
2018 Q2	$2.89K	Hold	24	–	–	﹤0.01%	1033
2018 Q1	$2.02K	Hold	24	–	–	﹤0.01%	1042
2017 Q4	$3.64K	Hold	24	–	–	﹤0.01%	1010
2017 Q3	$1.51K	Buy	+24	New	+$1.41K	﹤0.01%	1060

Other funds holding SRRA

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

RBC Europe's SRRA Position: Q4 2021 in Review

RBC Europe sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q4 2021, closing a stake of 24 shares — an estimated $526 sold.

RBC Europe first reported a position in SRRA in Q3 2017 and held it in 17 quarters. The position peaked at $3.64K in Q4 2017. 46 funds tracked by Wall St. Rank hold SRRA as of Q4 2021.

RBC Europe reported no remaining Sierra Oncology, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
RBC Europe sold 24 Sierra Oncology, Inc. Common Stock shares in Q4 2021, an estimated $526.
RBC Europe first reported a position in Sierra Oncology, Inc. Common Stock in Q3 2017 and held it in 17 quarters.
RBC Europe's Sierra Oncology, Inc. Common Stock position peaked at $3.64K in Q4 2017.
46 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.